anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a method for testing the drug sensibility of a tubercle bacillus, constituted so as to be simply and rapidly performed using a small amount of a culture medium and enhanced in safety, and also to provide a kit for testing the drug sensibility of the tubercle bacillus.  <P>SOLUTION: In the method for testing the drug sensibility of the tubercle bacillus, a specimen is cultured in a culture medium containing a tuberculostat and the obtained cultured medium is subjected to immunoassay to detect the tubercle bacillus strain specific secretory protein in the cultured medium as a tubercle bacillus marker. The specimen is cultured in a plurality of culture mediums containing tuberculostats different from each other so as to detect a multi-drug resistant tubercle bacillus and the obtained respective cultured mediums are preferably subjected to immunoassay. As the tuberculostat, isoniazid (INH), rifampicin (RFP), streptomycin (SM), ethambutol (EB), kanamycin (KM) or the like is used. As a control, it is preferable that the specimen is cultured in a culture medium containing no tuberculostat and the obtained cultured medium is preferably subjected to immunoassay. The immunoassay is preferably sandwich type immunoassay such as immunochromatography assay or the like.  <P>COPYRIGHT: (C)2010,JPO&INPIT
CX-4945 capsules at 1000mg/BID, 10-day continuous dosing (Day 0 through Day 9). PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
The study RD will meet individually with the Control group subjects in-person for 1-hour at the start of the 6-month intervention. Control participants will be instructed to maintain current eating and activity patterns and weight over the next 6 months. No dietary recommendations are provided, and they will receive weekly health newsletters that include non-diet related health topics (e.g., flu prevention). Contact will be made again at month-3 and post-intervention (month-6) research visits and during monthly phone calls to collect data pertaining to recent diet intake. At the month-3 assessment, weight will be checked and those with \>2.5% WL from baseline will receive additional instruction from the RD to maintain lifestyle patterns. All WL-Med materials are offered to the group in a self-guided format following the 6-month intervention.
The utility model relates to a means of immunotherapy and prophylaxis and finds application in urology in regards to infectious-inflammatory diseases of the urinary tract, particularly in mild to moderate lower urinary tract syptoms, associated with benign prostatic hyperplasia and prostatitis. The composition, according to this utility model, contains a bacterial mixture of lysate and bacterial cells of strains of five microbial species: Escherichia coli J5, Proteus mirabilis, Enterococcus faecalis, Кlebsiella pneumoniae, and highly concentrated nettle root extract (Urtica dioica) as one dose contains from 5 mg to 50 mg of the bacterial mixture and from 200 mg to 1000 mg of highly concentrated extract of nettle roots. The proposed means, according to the utility model, using the whole bacterial cells and their lysate provides complete stimulation of the whole body defence mechanisms. The strains thus selected and used induce broad-spectrum cross-immunity to the most common causes of uroinfections, not only E. coli but also Proteus, Klebsiella, Enterobacter, etc. as based on the generation of antibodies to the antigen-generating agent. The enriched composition with a highly concentrated nettle root extract additionally aids to the active bacterial mixture and phytosterols, lignans, tanning substances, beta-sitosterol, etc., thus determines the diuretic effect and enhances the anti-inflammatory effect in uroinfections. The added plant extract from nettle roots makes the agent more effective, having a complex effect on inflammatory diseases of the urinary tract, as well as ensuring a prolonged prophylactic and clinical effect. 5 claims
BACKGROUND: With expanding neurosurgical options in epilepsy, it is important to characterise each options' risk for postoperative cognitive decline. Here, we characterise how patients' preoperative white matter (WM) networks relates to postoperative memory changes following different epilepsy surgeries.
METHODS: Eighty-nine patients with temporal lobe epilepsy with T1-weighted and diffusion-weighted imaging as well as preoperative and postoperative verbal memory scores (prose recall) underwent either anterior temporal lobectomy (ATL: n=38) or stereotactic laser amygdalohippocampotomy (SLAH; n=51). We computed laterality indices (ie, asymmetry) for volume of the hippocampus and fractional anisotropy (FA) of two deep WM tracts (uncinate fasciculus (UF) and inferior longitudinal fasciculus (ILF)).
RESULTS: Preoperatively, left-lateralised FA of the ILF was associated with higher prose recall (p<0.01). This pattern was not observed for the UF or hippocampus (ps>0.05). Postoperatively, right-lateralised FA of the UF was associated with less decline following left ATL (p<0.05) but not left SLAH (p>0.05), while right-lateralised hippocampal asymmetry was associated with less decline following both left ATL and SLAH (ps<0.05). After accounting for preoperative memory score, age of onset and hippocampal asymmetry, the association between UF and memory decline in left ATL remained significant (p<0.01).
CONCLUSIONS: Asymmetry of the hippocampus is an important predictor of risk for memory decline following both surgeries. However, asymmetry of UF integrity, which is only severed during ATL, is an important predictor of memory decline after ATL only. As surgical procedures and pre-surgical mapping evolve, understanding the role of frontal-temporal WM in memory networks could help to guide more targeted surgical approaches to mitigate cognitive decline.
Candida infections can be serious in intensive care unit (ICU) patients, as Candida is an organism that specially colonizes the digestive system. In immunocompromised patients, treatment is protocolized, but in non-neutropenic patients, it is not well established. On the other hand, the treatment of this type of infection is not absent of adverse effects. The prevalence of fungal infections, especially candidiasis, and its mortality in the ICU is high, mainly due to the lack of diagnosis and absence of treatment criteria, because they are often detected in the disseminated candidiasis phase, such as candidemia. One of the indicators of the progression of the disease is the presence of Candida in more than two different foci, named Candida multifocality, within the concept of invasive candidiasis. In fact, the invasive fungal diseases in adult patients i intensive care unit (FUNDICU) project was created to optimize the management of candidiasis. The management of candidiasis in ICU patients first requires the identification of patients at high risk of candidiasis, which must be performed based on the evidence of immune dysregulation, higher severity index (acute physiologic assessment and chronic health evaluation and multiple organ dysfunction syndrome), long ICU stays or other factors such as mechanical ventilation or us of broad-spectrum antibiotics. To increase detection and dispense the appropriate antifungal at an early stage, it is necessary to include the concept of multifocality in invasive candidiasis with screening of different foci. Antifungal treatment reduces mortality both overall and attributable to Candida. Detecting a high invasive candidiasis risk is a patient safety concept and should be treated as such. Identifying patients (critically non-neutropenic adult patients with severe multiple organ dysfunction syndrome and the first isolation of Candida spp. in a study sample of possible secondary infection) and demonstrating invasive candidiasis (multifocal or disseminated) require urgent initiation of antifungal treatment to minimize mortality attributable to invasive candidiasis in the ICU and eliminate mortality rates above 50%.
Nasal and inhaled corticosteroids may result in the development of glaucoma and/or cataracts. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.

Glaucoma and cataract formation was evaluated with intraocular pressure measurements and slit lamp examinations in 1 controlled 12-month study in 806 adolescent and adult patients aged 12 years and older and in 1 controlled 12-week study in 558 children aged 2 to 11 years. The patients had perennial allergic rhinitis and were treated with either VERAMYST Nasal Spray (110 mcg once daily in adult and adolescent patients and 55 or 110 mcg once daily in pediatric patients) or placebo. Intraocular pressure remained within the normal range (<21 mmHg) in ≥98% of the patients in any treatment group in both studies. However, in the 12-month study in adolescents and adults, 12 patients, all treated with VERAMYST Nasal Spray 110 mcg once daily, had intraocular pressure measurements that increased above normal levels (≥21 mmHg). In the same study, 7 patients (6 treated with VERAMYST Nasal Spray 110 mcg once daily and 1 patient treated with placebo) had cataracts identified during the study that were not present at baseline.
The present invention discloses a combination of Chinese medicines for poultry and the preparation method and application. Hypericum forsythia and bidens grass are distilled. And then distilled liquid and residua are collected. The residua and the residual liquid after distillation being added with a hepatitis grass and a climbing nightshade are decocted three times. The decoction liquid is combined and concentrated to a thick concentration. A 95 percent ethanol is diluted to alcohol concentration of 60 percent to 70 percent. The drug liquid after sedimentation, filtration and concentration added with 95 percent ethanol are transferred to alcohol concentration of 75 percent to 80 percent and then are sedimentated and filtrated. The filtrate is concentrated. The drug liquid added with distilled water is frozenly precipitated, filtrated and concentrated. The combination of Chinese medicines is produced out after a combination of the distilled liquid of the hypericum forsythia and the bidens and the decoction liquid of the hepatitis grass and the climbing nightshade are combined. The combination of Chinese medicines has a cure rate of about 90% for a viruses and bacterial infectious disease of poultry, can be used to prepare the animal drug for treating duck viral hepatitis and chicken newcastle disease and has little side effect, safe use and fast absorption.
The Standard Care group will consume a diet consistent with the guidelines recommended by the American Diabetes Association that is high in non-starchy vegetables and lean protein sources and low in added sugar. Participants will receive isocaloric packed-out meals for 26 weeks.
Reproductive age women diagnosed with POR based on Poseidon criteria and POI based on European Society of Human Reproduction and Endocrinology (ESHRE) criteria with a history of at least one prior failed IVF cycle will recruited for the study. Antral follicle count (AFC), serum anti-mullerian hormone (AMH), and early follicular phase serum follicle stimulating hormone (FSH) levels will be determined at baseline. Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under sedation anesthesia, using a 35 cm 17 G needle under transvaginal ultrasound guidance. On the 2-4th days of the first six menstrual cycles following the procedure, AFC, AMH, and FSH levels will be re-assessed. Patients with at least one antral follicle will be started on ovarian stimulation for in-vitro fertilization- intracytoplasmic sperm injection (IVF-ICSI), followed by embryo banking/ preimplantation genetic testing- aneuploidy (PGT-A) or embryo transfer. Markers of ovarian reserve (AFC, FSH, AMH), and IVF laboratory outcome parameters (number of metaphase II (MII) oocytes, 2PN(pronucleus) embryos, cleavage stage, blastocyst embryos) will be followed.
Aurora Kinase A (AURKA) promotes cell proliferation and is overexpressed in different types of polycystic kidney disease (PKD). To understand AURKA's role in regulating renal cyst development we conditionally deleted the gene in mouse models of Autosomal Dominant PKD (ADPKD) and Joubert Syndrome, caused by Polycystin 1 (Pkd1) and Inositol polyphosphate-5-phosphatase E (Inpp5e) mutations respectively. We show that while Aurka is dispensable for collecting duct development and homeostasis, its deletion prevents cyst formation in both disease models. Cross-comparison of transcriptional changes implicated AKT signaling in cyst prevention and we show that (i) AURKA and AKT physically interact, (ii) AURKA regulates AKT activity in a kinase-independent manner and (iii) inhibition of AKT can reduce disease severity. AKT activation also regulates Aurka expression, creating a feed-forward loop driving renal cystogenesis. We find that the AURKA kinase inhibitor Alisertib stabilises the AURKA protein, agonizing its cystogenic functions. These studies identify AURKA as a master regulator of renal cyst development in different types of PKD, functioning in-part via AKT.
Medication errors happen frequently in hospital, home, and pharmacy environments. A medication verification and dispensing system provides protection against such errors. The apparatus includes a guide tube that receives a medication and imaging device(s) adjacent to the guide tube that take image(s) of the medication. The imaging devices(s) and light source(s) are oriented for capturing images that reveal markings, color, size, shape, etc., of the medication. A verification system uses a signature of the image to identify the medication or compares the image(s) to reference images to identify the medication and to a prescription record of the patient to ensure it is a correct medication, dose, amount, timing, etc., for administration. If the medication is correct, it is dispensed into a dispensing vessel that locks the medication inside, but unlocks when it recognizes a unique patient identifier worn by a patient that is a correct recipient for the medication.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, specifically dentistry and concerns treating temporomandibular joint arthrosis. For this purpose, mesenchymal cord and placental stem cells received after easy delivery. The cells 5-10106 are injected in the temporomandibular joint in 1-2 ml of patient's blood plasma and intra-articular fluid. taken from a patient's healthy major joint. ^ EFFECT: while being low-traumatic, the method provides replacement of articular cartilage defects, creating the environments for optimising the repair processes in treating the most severe and frequent temporomandibular joint injures. ^ 2 ex
Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
PURPOSE: To have a simple structure, have reliability in use, and hold high efficiency at the same time of removing plasma elements by diluting the blood by dilution before separating the plasma and removing the aforementioned dilution from the blood after mixing the treated plasma with blood cell element. CONSTITUTION: Blood is fed to a dilution device 4 by a blood feed device 1. In the early stage of the operation cycle, the dilution device 4 receives the dilution from a storage means B3 by operation of a pump P3. The dilution for the feed blood is thus present and it is fed to a separation filter F1 in an appropriate separation form. In this filter F1, plasma is separated and fed to a separation device F/A by a pump P2. The plasma is mixed with the blood cell in a mixing device 2. The blood cell passes through a buffer storage device B2 and is fed to a removal device F2 by a pump P5. Fractionation of the dilution which is present in the removal device F2 is fed to a return line 5 via the pump P3. The blood which passes through the removal device F2 and is returned to its original enrichment is fed to the body of a patient via a pump 4.
Remifentanil‑induced hyperalgesia (RIH) is characterized by the emergence of stimulation‑induced pain, including phenomena such as allodynia and thermal hyperalgesia following remifentanil infusion. As a sequence‑specific DNA binding transcription factor, PAX6 positively and negatively regulates transcription and is expressed in multiple cell types in the developing and adult central nervous system. It was hypothesized that puerarin could relieve RIH via targeting PAX6 to regulate transcription of transient receptor potential cation channel subfamily V Member 1 (TRPV1). A total of 32 rats were randomly divided into five groups, namely control group, RI group, RI + 10 mg/kg puerarin group (RI + puerarin10), RI + 20 mg/kg puerarin group (RI + puerarin20), and RI + 40 mg/kg puerarin group (RI + puerarin40). Mechanical and thermal hyperalgesia were tested at ‑24, 2, 6, 24 and 48 h after remifentanil infusion. Following the sacrifice of rats after the last behavioral test, western blot was used to detect the expression levels of TRPV1 in the tissues; Immunofluorescence staining and western blotting were used to detect the expression of PAX6 in the spinal cord. PharmMapper and JASPAR were used to predict the binding sites of puerarin/PAX6/TRPV1. Chromatin immunoprecipitation‑PCR and dual luciferase reporter assay were used to verify the targeting relationship between PAX6 and TRPV1. Immunofluorescence was used to detect the expression levels of TRPV1 and p‑NR2B. The results revealed that puerarin (10, 20, 40 mg/kg) dose‑dependently reduced thermal and mechanical hyperalgesia from 2 to 48 h after remifentanil infusion. Remifentanil infusion remarkably stimulated the expression of phosphorylated (p‑)NR2B. Nevertheless, the increased amount of p‑NR2B by RIH was dose‑dependently suppressed by puerarin in rats. In conclusion, puerarin was revealed to attenuate postoperative RIH via targeting PAX6 to regulate the transcription of TRPV1.
BACKGROUND AND PURPOSE: Ischemic stroke is a leading cause of mortality and disability globally, necessitating accurate prediction of intra-hospital mortality (IHM) for improved patient care. This study aimed to develop a practical nomogram for personalized IHM risk prediction in ischemic stroke patients.
METHODS: A retrospective study of 422 ischemic stroke patients (April 2020 - December 2021) from Chongqing Medical University's First Affiliated Hospital was conducted, with patients divided into training (n=295) and validation (n=127) groups. Data on demographics, comorbidities, stroke risk factors, and lab results were collected. Stroke severity was assessed using NIHSS, and stroke types were classified by TOAST criteria. Least absolute shrinkage and selection operator (LASSO) regression was employed for predictor selection and nomogram construction, with evaluation through ROC curves, calibration curves, and decision curve analysis.
RESULTS: LASSO regression and multivariate logistic regression identified four independent IHM predictors: age, admission NIHSS score, chronic obstructive pulmonary disease (COPD) diagnosis, and white blood cell count (WBC). A highly accurate nomogram based on these variables exhibited excellent predictive performance, with AUCs of 0.958 (training) and 0.962 (validation), sensitivities of 93.2% and 95.7%, and specificities of 93.1% and 90.9%, respectively. Calibration curves and decision curve analysis validated its clinical applicability.
CONCLUSION: Age, admission NIHSS score, COPD history, and WBC were identified as independent IHM predictors in ischemic stroke patients. The developed nomogram demonstrated high predictive accuracy and practical utility for mortality risk estimation. External validation and prospective studies are warranted for further confirmation of its clinical efficacy.
PURPOSE:A preventing and treating agent for immunological diseases containing a human interleukin 2 derived from humans. CONSTITUTION:A treating and preventing agent, containing a human interleukin 2 (IL-2), e.g. having 2X10<5> units/mg protein specific activity without containing the other human lymphokine and monocaine activity, derived from a human cell, e.g. a human lymphatic corpuscle, cloned cell thereof, human malignant cell or hybridoma, and effective for cancer, bacterial infection, viral diseases, immunological insufficiency or autoimmune diseases, etc. The human IL-2 is obtained by stimulating a lymphatic corpuscle obtained from a human peripheral blood, tonsil or spleen, etc. alone or in the presence of a phorbol ester for 12- 48hr with a phytohemagglutinin, concanavalin A or pretein A which is a T lymphatic corpsucle mitogen. The physical properties thereof are as follows: Molecular weight: 15,000. Inactivated with a proteolytic enzyme, thermally stable by heat-treating at 56 deg.C for 1hr and stable at 20-90pH.
The present invention relates to a method for preparing a fermented ginseng concentrate. The method first involves subjecting ginseng to an extraction with a solvent to obtain a ginseng extract. Next, pectinase and beta-galactosidase are added to the ginseng extract under conditions effective to ferment the ginseng extract. The fermented extract is then concentrated to produce a fermented ginseng concentrate. The method may further involve drying the fermented ginseng concentrate to obtain fermented ginseng powder. Combinations of the invention ginseng materials with other active and/or inactive materials are also disclosed.
The present invention relates to a method for extracting an antineoplastic component from ganoderma lucidum triterpene, particularly to a method for extracting a triterpene antineoplastic component from ganoderma lucidum by an ultrasonic circulating technique. The present invention relates to the field of a biological technique. The used raw material is a ganoderma lucidum seed solid. Main steps comprise six steps of ultrasonic circulating leaching, chloroform dissolution, ultrasonic circulating alkali extraction, hydrochloric acid acidification, ultrasonic circulating extraction and decompression evaporation. Compared with the prior art, the present invention has the advantages that the dosage of various required solvents is greatly reduced, the extraction time is greatly reduced, and the extraction rate of a product is enhanced by more than 25 %. Special ultrasonic circulating extraction equipment can be designed according to principle described by the present invention so that the equipment is suitable for industrialized production. The present invention has the advantages of production cost reduction, production period shortening and product yield enhancement.
Stimulation on from activation to 12 weeks post-activation. Stimulation off from 12 weeks post-activation to 16 weeks post-activation. Stimulation on from 16 weeks post-activation to end of study.
A heavier blanket will be worn overnight for 3 months. Blanket weight cannot be disclosed without unblinding participants.
The patients with advanced HIV disease that receive HIV care at the intervention clinics will receive the enhanced intervention package which will include: point of care CD4 testing with visitect, screening for TB and cryptococcal meningitis using Fujifilm LAM and semiquantitative crAg LFA respectively and pre-emptive treatment with isoniazid and rifapentine for one month. Those with a high crAg titers will receive treatment for CNS cryptococcal disease.